



Study Published in *Antimicrobial Agents and Chemotherapy* Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly *Candida Auris* Fungus

Candida auris deemed urgent threat by Centers for Disease Control and Prevention

Durham, N.C. - April 11, 2019 - [Mycovia Pharmaceuticals](#), a developer of breakthrough drugs in women's health, today announced that oral drug candidate VT-1598 has shown in vitro and in vivo activity against *Candida auris*, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat. NovaQuest Capital Management formed Mycovia in 2018 and recently acquired VT-1598, which Mycovia is developing to combat serious fungal pathogens. The results of the study on *Candida auris* were published in the March issue of *Antimicrobial Agents and Chemotherapy*, a journal of the American Society for Microbiology.

Susceptibility testing was conducted by the Fungal Reference Laboratory at the Centers for Disease Control and Prevention (CDC) where VT-1598 demonstrated in vitro activity against 100 clinical isolates of *Candida auris*. In addition, treatment with VT-1598 resulted in significant and dose-dependent improvements in survival and reduction in kidney and brain fungal burden compared to control in mice infected with *Candida auris*. These results suggest that VT-1598 may be a future option for the treatment of invasive infections caused by *Candida auris*.

"As a women's health organization, Mycovia is passionate about developing breakthrough drugs in areas of significant unmet medical needs. Concurrently, we realize that there is tremendous potential for oral fungal inhibitors to treat multi-drug resistant fungal pathogens such as *Candida auris* which is virulently spreading across the globe," said Patrick Jordan, Chief Executive Officer of Mycovia and Partner at NovaQuest Capital Management. "While women's health remains our number one priority as we move through Phase 3 clinical trials with the goal to be the first FDA-approved treatment for recurrent vulvovaginal candidiasis, we continue to assess and commence new opportunities where Mycovia can address tremendous unmet medical needs."

The CDC recently deemed *Candida auris* a global emerging threat. This pathogen typically strikes people in hospitals with compromised immune systems and contributes to the growing health threat associated with drug-resistant infections.

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals has a passion for developing breakthrough drugs in women's health. Our lead product candidate, oteseconazole, is a novel, oral therapy for recurrent vulvovaginal candidiasis (RVVC). RVVC is commonly known as a chronic yeast infection and is often accompanied by severe physical discomfort and emotional burden. Our goal is to restore quality of life while empowering millions of women worldwide. For more information, please visit www.mycovia.com

About NovaQuest

NovaQuest Capital Management is a leading investor in life sciences and healthcare through its Product Finance and Private Equity strategies. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital to life sciences and healthcare companies. Today, NovaQuest Capital Management manages over \$2 billion through its Product Finance and Private Equity strategies. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.

Contacts

Mycovia Pharmaceuticals
Stephen Brand, Ph.D., 919-467-8539
sbrand@mycovia.com

Media

MacDougall Biomedical Communications
Lauren Arnold, 781-235-3060
larnold@macbiocom.com